BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2020

View Archived Issues

Evaluation of 18F-FPIA, a radiotracer for SCFA metabolism, in fed and fasted healthy volunteers

Read More

Antiviral novaferon exhibits anti-SARS-CoV-2 effects both at cellular level and in COVID-19 patients

Read More

ValiRx presents full updated data from its phase I/II study of VAL-201 in prostate cancer

Read More

Braftovi and Mektovi approved in Japan for additional indication of BRAF-mutant colorectal cancer

Read More

Allena presents initial phase I data on ALLN-346 for hyperuricemia

Read More

Deciphera completes target enrollment in INTRIGUE trial of Qinlock in second-line GIST

Read More

Gain Therapeutics and UMSOM collaborate to develop novel STAR candidates

Read More

Voyager Therapeutics patents vector-based systems of augmenting protein destruction

Read More

Deepmind program can predict protein structures

Read More

Plus Therapeutics presents phase I data for RNL in recurrent glioblastoma

Read More

Kiniksa reports initial phase I data on KPL-404

Read More

Istari initiates phase II trial of PVSRIPO with pembrolizumab in recurrent GBM

Read More

Evinacumab shows promise in patients with refractory hypercholesterolemia

Read More

Galapagos reports topline phase II proof-of-concept data with GLPG-1205 in IPF

Read More

Lumicef approved in Japan for AS and nonradiographic axial spondyloarthritis

Read More

DMX-200 selected for inclusion in CLARITY 2.0 study for COVID-19

Read More

PTC initiates phase III study of vatiquinone for Friedreich's ataxia

Read More

Verastem opens phase II study of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer

Read More

New phase IIb trial evaluates ability of AZD-8233 to lower LDL-C

Read More

New COMMUNITY adaptive platform trial for COVID-19 begins enrollment

Read More

Latexin expression promotes development of abdominal aortic aneurysm

Read More

Integral Early Discovery, Integral Health Holdings discover ZRANB1 inhibitors

Read More

New KCNT1 inhibitors identified at Praxis Precision Medicines

Read More

Nirsum Laboratories presents prodrugs of opioid receptor antagonists

Read More

New PDE6D inhibitors discovered at the University of Luxembourg

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing